SBFM: Sunshine Biopharma Inc. Price Target Chart

Symbol and logo of brand sunshinebiopharma.com (SBFM)

Sunshine Biopharma focuses on overcoming tumor therapy resistance using small molecules. Simultaneously, the business relies on mRNA gene silencing technologies for the targeted suppression of pathogens, which minimizes toxicity. The current metric is 1121.46. Securities price action on GURU.Markets underscores the resilience of Sunshine Biopharma, which is protected by complex FDA regulations and patents for the treatment of solid neoplasms.

Sunshine Biopharma (SBFM) - Price Target Chart from 07/04/2022 to 11/11/2026
Original product of Sunshine Biopharma, Inc.

Assessing the prospects of Sunshine Biopharma (SBFM) requires a deep fundamental analysis, where the history of analyst targets on GURU.Markets reflects the average expected share price as an indicator of potential growth points. This metric allows for a comparison of market expectations against the company's high margins and patent protection for its drugs, determining the fair capital upside against a backdrop of stable cash flow.

Competing companies

Analyst Median Target beigene.com|Analyst Consensus Forecast HALO (Halozyme)|Revolution Medicines Inc - Price Target Chart|Ascentage - Analyst Consensus Forecast|Forecast Levels Chart CGON|UroGen Pharma Ltd. (URGN) - Price Target Chart|Consensus Target bicara.com|PSNL (Personalis) - Analyst Consensus Forecast|Consensus Target Erasca Inc (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast Y-mAbs Corp (YMAB)|Price Target Chart Aura Biosciences, Inc. AURA|CADL: Broker Consensus Forecast|Accuray - Analyst Consensus Forecast|SELLAS Life Sciences (SLS) - Consensus Target|ACTU: Analyst Consensus Forecast|Average Forecast Price Citius Oncology Inc (CTOR)|Price Target Chart TuHURA Biosciences Inc.|TARA: Fair Value Consensus|Consensus Target FATE (Fate Therapeutics)|WHWK (aadibio.com) - Fair Value Consensus|Analyst Consensus Forecast TCRX (TScan Therapeutics, Inc.)|CSBR - Consensus Target|XBIT: Consensus Target|CVM - Analyst Consensus Forecast|OS Therapies (OSTX) - Price Target Chart|Radiopharm Theranostics Ltd - Fair Value Consensus|ARTV (Artiva Biotherapeutics Inc.) - Analyst Consensus Forecast|Average Forecast Price Adlai Nortye Limited ANL|Price Target Chart Veru Inc. (VERU)|Analyst Median Target tempesttx.com|Xilio Therapeutics - Consensus Target|Analyst Consensus Forecast Renovaro Biosciences RENB|MURA - Price Target Chart|KAPA (Kairos Pharma Ltd) - Broker Consensus Forecast|onkuretherapeutics.com (OKUR) - Price Target Chart|GDTC - Analyst Median Target|CRIS (Curis Inc.) - Analyst Consensus Forecast|APLM: Fair Value Consensus|Analyst Consensus Forecast THAR|Analyst Median Target advanbiomed.com|Price Target Chart Genprex, Inc. GNPX|CLDI: Broker Consensus Forecast|Xenetic Bio - Analyst Consensus Forecast|Average Forecast Price Salarius Pharmaceuticals Inc|PPBT (Purple Biotech Corp) - Consensus Target|American Oncology Network, Inc. - Fair Value Consensus|BGNE (BeiGene, Ltd.) - Analyst Consensus Forecast|Price Target Chart CKPT|Analyst Consensus Forecast ELEV|Analyst Median Target icadmed.com|Price Target Chart Ikena Oncology IKNA|Notable Labs Corp (NTBL) - Average Forecast Price|VIRX - Price Target Chart|Forecast Levels Chart MOR|NAYA: Analyst Consensus Forecast|Ascentage Pharma Group International - Fair Value Consensus